Treatment of hemophilia with inhibitor. Royal Victoria Eugenia Foundation

The Royal Victoria Eugenia Foundation promotes the publication of the guide "Recommendations for the treatment of Hemophilia with Inhibitor".

In recent years we are witnessing an unprecedented advance in the treatment of patients with hemophilia. In patients with hemophilia and inhibitor these advances are especially relevant and accessible in the immediate future for the daily routine. A new class of therapeutic agents has been established that act by improving coagulation (emicizumab) and inhibiting the anticoagulant pathways (fitusiran and concizumab), which function as useful products in the prophylaxis of bleeding in this group of patients. However, information is still needed on its long-term safety and handling of possible complications of its use. In addition, we need to implement laboratory techniques to evaluate the haemostatic function of patients treated with these products and their combination with baipal agents and factors VIII and IX in case of surgery or acute bleeding. Finally, other areas of evaluation are opened, such as the role of immunotolerance at present.

The following guide aims to review the new perspectives of the treatment of inhibitor patients regarding both the prevention and treatment of bleeding and surgical episodes. The objective is to serve as an aid in the indication, monitoring and evaluation of these new therapies.